Matches in Nanopublications for { ?s ?p "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 13 of
13
with 100 items per page.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP1247128.RAajNaz7Myw2CV9n8Md1DN2o0YoeyqEXL26BWvztycj8o130_assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247128.RAajNaz7Myw2CV9n8Md1DN2o0YoeyqEXL26BWvztycj8o130_provenance.
- NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247127.RAlMtzEqQesJbdVZzW-JhdU3Yz2iYd6EEU6sZw94x5Tjg130_provenance.
- NP1247133.RAqP5Rj5Kj5Q9XbuVGf4VfqjmQ1pvlPRqmi6wmzt2CSDY130_assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247133.RAqP5Rj5Kj5Q9XbuVGf4VfqjmQ1pvlPRqmi6wmzt2CSDY130_provenance.
- NP1247134.RApKKZHO7sOOQGR8cwOLC44FEzWUbF3U7ZsAVnWyhla58130_assertion description "[Thus, we conclude that p53 deficiency and KRAS mutation activate the NF-?B signaling to control chemoresistance and tumorigenesis, and that the status of p53 and KRAS may be considered for the targeted therapy against NF-?B in lung cancer patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1247134.RApKKZHO7sOOQGR8cwOLC44FEzWUbF3U7ZsAVnWyhla58130_provenance.